Loncastuximab tesirine是一种靶向人CD19的抗体-活性分子偶联物（ADC），由抗体部分 Loncastuximab 与毒性分子-linker 偶联物 Tesirine 构成。该药物与细胞膜CD19结合后可迅速内化，通过诱导细胞凋亡引发细胞死亡，适用于弥漫型B细胞淋巴瘤的相关研究。

[1] Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. Blood. 2021.[2]Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S, D'Hooge F, Williams DG, Tiberghien A, Howard PW, Hartley JA, van Berkel PH. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131(10):1094-1105. doi: 10.1182/blood-2017-10-813493. Epub 2018 Jan 3. PMID: 29298756.